DICE Therapeutics, Inc.
DICEDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645569
DICE Therapeutics, Inc. was delisted in 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 160
- Q2 2023, +45 vs. previous quarter
- 13F value
- $2.12B
- Reported value at the end of Q2 2023
- Superinvestors holding
- 1
- At the end of Q2 2023
Superinvestors holding DICE, Q2 2023
1 superinvestor reports holding DICE Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Fairfax Financial
Prem Watsa
0.3%
DICE Therapeutics, Inc.'s share of the portfolio
- Shares
- 130,000
- Value
- $6.04M
Latest insider trades
Open-market purchases and sales by DICE Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2023 (view filing)5:36 PM ET | Jun 22 | 1 day | Northpond Ventures GP, LLC and 4 others10% Owner | SSale | −2.49M | $46.50 | −$115.9M | −93.7%166.3K after | 2 lots |
| Jun 2, 2023 (view filing) | Jun 1 | 1 day | Jacobsen John R.CSO | SSale | −18.8K | $30.53 | −$572.4K | −11.3%147.5K after | 2 lots |
| May 9, 2023 (view filing) | May 5 | 4 days | Scheller Richard HDirector | SSale | −84.1K | $38.51 | −$3.24M | −90.9%8.43K after | |
| May 5, 2023 (view filing) | May 3 | 2 days | Robertson Scott M.CFO & CBO | SSale | −18.8K | $36.55 | −$685.3K | −8.7%198.0K after | |
| May 5, 2023 (view filing) | May 3 | 2 days | Timothy LuCMO | SSale | −10.0K | $36.54 | −$365.4K | −6.2%152.3K after | |
| May 5, 2023 (view filing) | May 3 | 2 days | Judice KevinCEO | SSale | −13.7K | $36.50 | −$500.0K | −1.7%799.7K after | |
| Apr 19, 2023 (view filing) | Apr 18 | 1 day | Jacobsen John R.CSO | SSale | −16.4K | $30.08 | −$493.1K | −9.0%166.2K after | |
| Apr 4, 2023 (view filing) | Mar 31 | 4 days | Jacobsen John R.CSO | SSale | −773 | $30.00 | −$23.2K | −0.4%182.6K after | |
| Mar 30, 2023 (view filing)5:03 PM ET | Mar 28-30 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +509.1K | $29.07 | +$14.8M | +7.8%7.07M after | 3 lots |
| Mar 30, 2023 (view filing) | Mar 28-29 | 2 days | Jacobsen John R.CSO | SSale | −1.59K | $30.03 | −$47.9K | −0.9%183.4K after | 2 lots |
Top 10 13F holders, Q2 2023
The largest institutional positions in DICE Therapeutics, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 7,856,612 | $365.0M | 6.89% | 00.0% | Unchanged |
| BlackRock Inc. | 2,895,307 | $134.5M | 0.00% | −117,134−3.9% | Reduced |
| FMR LLC | 2,239,223 | $104.0M | 0.01% | −3,441,317−60.6% | Reduced |
| Avoro Capital Advisors LLC | 2,199,342 | $102.2M | 1.39% | −1,750,658−44.3% | Reduced |
| Alpine Associates Management Inc. | 2,116,800 | $98.3M | 4.43% | +2,116,800 | New |
| Driehaus Capital Management LLC | 2,038,257 | $94.7M | 1.20% | +36,704+1.8% | Added |
| Vanguard Group Inc | 1,957,417 | $90.9M | 0.00% | +29,161+1.5% | Added |
| Magnetar Financial LLC | 1,155,887 | $53.7M | 1.18% | +1,155,887 | New |
| Pentwater Capital Management LP | 1,080,507 | $50.2M | 0.63% | +1,080,507 | New |
| UBS Oconnor LLC | 1,075,000 | $49.9M | 1.06% | +1,075,000 | New |